Genzyme forms new division with acquisition:
This article was originally published in Clinica
Executive Summary
Genzyme is to acquire PharmaGenics and create a new division, Genzyme Molecular Oncology, which will develop molecular approaches to cancer diagnosis and therapy. With the acquisition, which is expected to close in May, Genzyme will create a third tracking stock in addition to its General Division and Tissue Repair Division. The shareholders of PharmaGenics will receive 40% of the shares in the Molecular Oncology Division. Shareholders of Genzyme General Division will receive the other 60% after an initial public offering later this year which will list the new division on Nasdaq.
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.